Latest News:

ar de elenfr it

TIF

FDA grants Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease & β-thalassaemia

An investigational gene therapy for Sickle Cell Disease (SCD) and β-thalassaemia, known as AR...
Chiesi Group and Apotex Inc. finalize agreement for the acquisition of Ferriprox® (Deferiprone)

Chiesi Farmaceutici and Apotex (together with its American subsidiary, ApoPharma Usa), a comp...
TIF’s latest Newletter is out now!

Catch up with our most recent newsletter and get informed about TIF’S activities and achieveme...
LOVING LIFE ENOUGH by Mary Manachi

This is the story of the late Mrs. Mary Manachi from New Jersey, USA, who lost 3 children from thala...
Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany

Bluebird bio, Inc. announced earlier today the launch of ZYNTEGLO™ in Germany, the company&...

Highlights

TIF e-AcademyAcadémie électronique de la FITe-Academyالأكاديمية الإلكترونية للاتحاد الدولي للثلاسيمياΗλεκτρονική ΑκαδημίαTIF e-Akademie

Patient Advocacy ProgrammePatient Advocacy ProgrammePatient Advocacy ProgrammePatient Advocacy ProgrammePatient Advocacy ProgrammePatient Advocacy Programme

Clinical Trial UpdatesEssais cliniques - Mises à jourAggiornamenti sugli studi cliniciآخر مستجدات التجارب الإكلينكية Ενημερώσεις για κλινικές δοκιμέςUpdate zu klinischen Studien

Renzo Galanello FellowshipsBourses Renzo GalanelloBorsa di studio Renzo Galanelloمنحة رينزو جالانيلوΥποτροφίες Renzo GalanelloRenzo Galanello Stipendien

International Thalassaemia DayJournée Mondiale de la ThalassémieGiornata internazionale della talassemiaاليوم العالمي ’للثلاسيميا’Παγκόσμια Ημέρα ΘαλασσαιμίαςInternationaler Tag der Thalassämie

The THALIA ProjectThe THALIA ProjectThe THALIA ProjectThe THALIA ProjectThe THALIA ProjectThe THALIA Project

Supporters Sympathisants Sostenitori الداعمون Οι Υποστηρικτές μας Unterstützer